Jul 20, 2018 • 9:20 am EDT Corbus Pharmaceuticals Receives FDA Orphan Drug Designation for Lenabasum for the Treatment of Dermatomyositis
Jun 21, 2018 • 8:00 am EDT Corbus Pharmaceuticals Announces Resolution of Inflammation, Infection and Tissue Regeneration Conference
Jun 14, 2018 • 8:25 am EDT Corbus Pharmaceuticals to Present at the JMP Securities Life Science Conference
Jun 13, 2018 • 9:29 am EDT Corbus Pharmaceuticals Presents 1-Year Systemic Sclerosis and 6-Month Dermatomyositis Data from Open-Label Extension of Phase 2 Lenabasum Studies at EULAR 2018
Jun 6, 2018 • 7:05 am EDT Corbus Pharmaceuticals Appoints Former Director of FDA Office of New Drugs John K. Jenkins, MD to Board of Directors
May 24, 2018 • 8:00 am EDT Corbus Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
May 22, 2018 • 8:00 am EDT Corbus Pharmaceuticals Adds Two Key Executives to Lead its Regulatory and CMC Operations
May 15, 2018 • 8:00 am EDT Corbus Pharmaceuticals Announces Acceptance of Three Abstracts for Presentation at EULAR 2018 Annual Meeting
May 10, 2018 • 8:00 am EDT Corbus Pharmaceuticals Reports 2018 First Quarter Financial Results and Provides Business Update
Apr 26, 2018 • 8:00 am EDT Corbus Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference